Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Genetically engineered organs for early reporting of transplant rejection

Molecular Therapy(2025)10.1016/j.ymthe.2025.10.024Source: DataRank Database

Genetically engineered organs for early reporting of transplant rejection is a research paper published in Molecular Therapy (2025). On theSindex it has a DataRank of 0.165. It has been cited 2 times.

N/A

0.165DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.80)OA: bronzeTopics (46)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.165

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (16)

Raphaela Bento ORCID,Antonia T. Dinicu,Christopher Taveras,Madeeha Hassan,Mohammadreza Mojoudi

Live enrichment

PubMed:41088753 OpenAlex:https://openalex.org/W4415227080

National Science Foundation

Grant: EEC 1941543

National Science Foundation

Grant: 84302-BOS-21

Shriners Children's Boston

Grant: 85105-BOS-23

National Institutes of Health

Grant: R01EB028782

FWCI

0.80

Citation Percentile

0.7%

Citation Trend

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttps://www.cell.com/molecular-therapy-family/molecular-therapy/pdf/S1525-0016(25)00845-7.pdf

publisherhttps://www.cell.com/molecular-therapy-family/molecular-therapy/pdf/S1525-0016(25)00845-7.pdf

publisherhttps://api.elsevier.com/content/article/PII:S1525001625008457?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1525001625008457?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ymthe.2025.10.024

Fields of Study

Pluripotent Stem Cells ResearchTissue Engineering and Regenerative MedicineCRISPR and Genetic EngineeringGraft RejectionHumansAnimalsGenetic VectorsLentivirusGenetic EngineeringMiceLuciferasesTransgenesPromoter Regions, GeneticGenes, ReporterGraft SurvivalNF-kappa B

MeSH Terms

AnimalsGenetic EngineeringGenetic VectorsGraft RejectionGraft SurvivalHumansLuciferasesPromoter Regions, GeneticLentivirusNF-kappa BGenes, ReporterTransgenesMice

Keywords

TransgeneEx vivoIn vivoTransplantationReporter geneGenetically engineeredMachine perfusionTransplant rejectionGenetic engineeringBiosensorOrgan transplantationGenetic modificationLentivirusDiagnosticsVascularized Composite AllograftsWhole OrgansEx Vivo Preservation